NASDAQ:IMMU - Immunomedics, Inc.
$17.28
 $0.56
+3.37%
4:00PM EDT
2019-09-16
Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  IMMU     avg for
industry  
  avg for
sector  
42 stocks weight:  94. 07   0. 00   0. 00  
42 stocks rank:  2. 77 K 1. 97 K 1. 30 K
# analyst opinions:  11. 00   12. 84   12. 97  
mean recommendation:  2. 00   2. 12   2. 07  

quick ratio:  9. 71   5. 11   1. 92  
current ratio:  9. 93   5. 50   2. 45  

target price low:  14. 00   79. 53   109. 66  
target price avg:  25. 45   100. 11   131. 81  
target price high:  40. 00   126. 46   149. 31  
1-yr high:  24. 52   104. 28   134. 46  
last close:  17. 32   77. 07   117. 08  
50-day avg:  14. 51   79. 01   117. 12  
200-day avg:  15. 51   81. 51   113. 76  
1-yr low:  11. 98   62. 18   93. 76  
volume:  2. 34 M 2. 53 M 3. 04 M
50-day avg volume:  1. 88 M 3. 41 M 4. 09 M
200-day avg volume:  2. 72 M 3. 18 M 4. 63 M

1-day return:  3. 59 % -0. 17 % 0. 18 %
this week return:  3. 59 % 0. 31 % 0. 77 %
12-wk return:  24. 87 % -0. 76 % 2. 99 %
52-wk return:  -30. 26 % -5. 78 % 4. 64 %

enterprise value (EV):  2. 60 B 44. 28 B 112. 94 B
market cap:  3. 32 B 500. 31 B 4. 95 T
EBITDA:  -340. 50 M 4. 78 B 7. 74 B
enterprise multiple (EV/EBITDA):  -7. 64   2. 41   10. 42  
enterprise/revenue (EV/R):  -3. 00 K 150. 10   22. 18  
total revenue:  -868. 00 K 10. 73 B 31. 64 B
total debt:  17. 49 M 11. 92 B 16. 97 B
debt/equity:  15. 27   244. 15   141. 17  
net income (common):  -326. 05 M 1. 86 B 3. 90 B

shares outstanding:  191. 98 M 579. 09 M 1. 27 B
shares:  162. 64 M 584. 68 M 1. 22 B
shares short:  37. 54 M 16. 45 M 13. 52 M
shares short prior month:  38. 14 M 15. 17 M 12. 50 M
short ratio:  22. 31   6. 82   3. 68  
short % of float:  24. 88 % 7. 00 % 2. 78 %
total cash/share:  2. 25   10. 27   8. 82  
total cash:  432. 65 M 6. 23 B 5. 99 B
operating cash flow:  -258. 85 M 4. 10 B 5. 77 B

book value:  0. 60   13. 01   26. 68  
price/book:  28. 77   -9. 86   6. 12  
gross profits:  -187. 77 M 8. 13 B 35. 94 B
operating margins:  39845. 97 % -1246. 94 % -202. 61 %
EBITDA margins:  0. 00 % 7. 07 % 24. 32 %
profit margins:  0. 00 % 3. 12 % 14. 56 %
gross margins:  0. 00 % 44. 41 % 58. 52 %

1-yr max volatility:  26. 32 % --- ---
1-yr mean volatility:  2. 96 % 1. 19 % 0. 86 %

1-yr EPS:  -1. 63   1. 30   4. 02  
forward EPS:  -1. 50   3. 42   6. 65  
P/E:  -10. 62   15. 96   23. 91  
forward P/E:  -11. 15   -4. 28   12. 40  
PE/G:  1. 43   1. 02   -1. 71  
growth:  -7. 40 % 218. 69 % 102. 21 %
earnings high:  -0. 10   1. 22   1. 61  
earnings avg:  -0. 37   0. 85   1. 50  
earnings low:  -0. 44   0. 55   1. 39  
revenue high:  62. 10 M 2. 88 B 8. 82 B
revenue avg:  8. 01 M 2. 80 B 8. 66 B
revenue low:  -0. 00   2. 75 B 8. 48 B
revenue/share:  -0. 00   13. 15   52. 14  

beta (1yr vs S&P500):  1. 59   1. 20   0. 87  
sharpe (1yr):  -0. 03   -0. 09   0. 48  

held % insiders:  7. 19 % 6. 78 % 3. 59 %
held % institutions:  84. 82 % 76. 29 % 67. 25 %

Research more with google or yahoo!
the data below are updated and re-published at 8pm EDT after each trading day

2019-09-16 : IMMU
.     124.26 =          124.26 :: --> INITIAL WEIGHT <--
.                               --> FUNDAMENTALS <--
.    x 1.632 =         202.851 :: P/E factor
.    x 0.988 =          200.39 :: PE/G factor
.     x 1.55 =         310.648 :: beta factor
.    x 0.863 =         268.146 :: sharpe factor
.    x 1.243 =         333.195 :: current ratio factor
.    x 0.875 =         291.712 :: quick ratio factor
.    x 1.027 =         299.725 :: short ratio factor
.    x 1.209 =         362.499 :: price-to-book factor
.    x 2.291 =         830.551 :: debt-to-equity factor
.                               --> PERFORMANCE <--
.    x 2.037 =        1692.235 :: sector+industry 1-year gains factor
.    x 0.979 =        1656.084 :: industry 12-weeks return factor
.    x 1.315 =        2178.381 :: industry 2-weeks return factor
.    x 0.981 =        2136.293 :: company one-year gains+dividend factor
.    x 6.307 =       13473.904 :: company 13 weeks' performance factor
.    x 1.112 =       14986.963 :: 5-day avg > 200-day avg
.     x 1.54 =       23083.604 :: 5-day avg > 50-day avg
.    x 0.998 =       23047.083 :: "drift" penalty 2 days ago
.    x 0.999 =       23015.716 :: "drift" penalty 5 days ago
.     x 3.75 =       86311.332 :: overall "drift" factor
.    x 0.836 =       72158.845 :: largest single-day price delta factor
.    x 0.996 =       71858.164 :: volatility factor
.    x 0.996 =        71551.82 :: 42-day volatility factor
.    x 2.096 =      149974.486 :: inverse volume-to-price factor
.                               --> PROJECTIONS <--
.    x 0.865 =      129766.954 :: forward P/E factor
.    x 1.183 =       153529.28 :: industry recommendation factor
.    x 2.246 =      344762.215 :: company recommendation factor
.    x 1.006 =      346997.077 :: factor historical industry gain for week 37
.    x 0.974 =      338022.776 :: target low factor
.    x 1.228 =      415218.997 :: target mean factor
.    x 1.048 =      435175.024 :: target high factor
.   x 10.444 =     4545065.186 :: spline projection factor
.                               --> FINAL ADJUSTMENTS <--
.  quad root =          46.173 :: reduced for readability
.   + 47.901 =          94.073 :: add/subtract for investor sentiment
.                               --> FINAL WEIGHT <--
.                     94.073 :: FINAL WEIGHT for NASDAQ:IMMU


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org